Kailera’s Oral GLP-1 Drug Meets Primary Endpoints in Chinese Phase 3 Obesity and Diabetes Trials
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- Kailera's oral GLP-1 receptor agonist demonstrated efficacy in Phase 3 trials for both obesity and type 2 diabetes in China, achieving primary endpoints.
- The trials reported an average weight loss of 11% in participants, indicating significant therapeutic potential for metabolic syndrome management.
- This oral formulation mimics the action of endogenous glucagon-like peptide-1 (GLP-1), a hormone crucial for regulating glucose homeostasis and satiety.
- Successful development of an oral GLP-1 therapy addresses a critical unmet need for improved patient adherence compared to existing injectable formulations.
- The positive results pave the way for regulatory submission by Hengrui Pharma in China, potentially expanding access to this therapeutic class.
- Advances in oral peptide delivery, exemplified by this development, hold promise for the future of administering other biologics traditionally requiring injection.
Kailera Therapeutics has announced that its oral GLP-1 receptor agonist achieved its primary endpoints in Phase 3 clinical trials for obesity and type 2 diabetes conducted in China. The trials reported an average 11% weight loss among participants. The positive results position Kailera’s partner, Hengrui Pharma, to file for regulatory approval in China for both indications.
The drug is an oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of therapies that mimic a natural hormone to regulate blood sugar and appetite. The Phase 3 data support the asset’s efficacy in weight reduction and glycemic control.
GLP-1 receptor agonists have become a cornerstone of metabolic disease treatment, with injectable versions widely used. An effective oral option could improve patient adherence by eliminating the need for injections. The successful Chinese trials mark a step toward bringing an oral GLP-1 therapy to a large patient population. Advances in oral peptide delivery also have broader implications for the development of other biologic drugs that are traditionally administered by injection.
Source: original report